<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">32790837</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2055-6845</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>FI1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>European heart journal. Cardiovascular pharmacotherapy</Title>
          <ISOAbbreviation>Eur Heart J Cardiovasc Pharmacother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.</ArticleTitle>
        <Pagination>
          <StartPage>f30</StartPage>
          <EndPage>f39</EndPage>
          <MedlinePgn>f30-f39</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjcvp/pvaa079</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS">Non-vitamin K oral anticoagulants are safe and effective for stroke prevention in patients with atrial fibrillation (AF). Data on the safety and efficacy of edoxaban in routine care are limited in Europe. We report 1-year outcomes in patients with AF treated with edoxaban in routine care.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS">ETNA-AF-Europe is a prospective, multicentre, post-authorization, observational study enrolling patients treated with edoxaban in 10 European countries, the design of which was agreed with the European Medicines Agency as part of edoxaban's post-approval safety plan. Altogether 13 092 patients in 852 sites completed the 1-year follow-up [mean age: 73.6 ± 9.5 years; 57% male, mean follow-up: 352 ± 49 days (median: 366 days)]. Most patients had associated comorbidities (mean CHA2DS2-VASc score: 3.1 ± 1.4). Stroke or systemic embolism was reported in 103 patients (annualized event rate: 0.82%/year), and major bleeding events were reported in 132 patients (1.05%/year). Rates of intracranial haemorrhage were low [30 patients (0.24%/year)]. Death occurred in 442 patients (3.50%/year); cardiovascular (CV) death occurred in 206 patients (1.63%/year). The approved dosing of edoxaban was chosen in 83%. All-cause and CV mortality were higher in patients receiving edoxaban 30 mg vs. 60 mg, in line with the higher age and more frequent comorbidities of the 30 mg group. Major bleeding was also numerically more common in patients receiving edoxaban 30 mg vs. 60 mg.</AbstractText>
          <AbstractText Label="CONCLUSION">The rates of stroke, systemic embolism, and major bleeding are low in this large unselected cohort of high-risk AF patients routinely treated with edoxaban.</AbstractText>
          <CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>de Groot</LastName>
            <ForeName>Joris R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Amsterdam University Medical Centres/University of Amsterdam, Spui 21 1012 WX Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weiss</LastName>
            <ForeName>Thomas W</ForeName>
            <Initials>TW</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Cardiometabolic Diseases, Karl Landsteiner Society, St. Pölten, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kelly</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, HRB Stroke Clinical Trials Network Ireland, University College Dublin/Mater Misericordiae University Hospital, Eccles St, Northside, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Monteiro</LastName>
            <ForeName>Pedro</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Centro Hospitalar e Universitário de Coimbra, Praceta Mota Pinto 3000-075, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deharo</LastName>
            <ForeName>Jean Claude</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>AP-HM, Aix Marseille University, Hôpital Timone, Cardiologie, Rythmologie, 264 rue Saint-Pierre, 13005, Marseille, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Asmundis</LastName>
            <ForeName>Carlo</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Universitair Ziekenhuis Brussels, Ninoofsesteenweg 134, 1700 Dilbeek, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>López-de-Sá</LastName>
            <ForeName>Esteban</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiological Intensive Care Unit, Cardiology Service, Hospital Universitario La Paz, IDIPAZ, CIBER-CV, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Waltenberger</LastName>
            <ForeName>Johannes</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, University of Munster, Schlossplatz 2, 48149 Münster, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine I, SRH Central Hospital Suhl, Albert-Schweitzer-Straße 2, 98527 Suhl, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Steffel</LastName>
            <ForeName>Jan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, University Hospital of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Levy</LastName>
            <ForeName>Pierre</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Economics, Université Paris-Dauphine, PSL Research University, LEDa-LEGOS, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bakhai</LastName>
            <ForeName>Ameet</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zierhut</LastName>
            <ForeName>Wolfgang</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Daiichi Sankyo Europe GmbH, Zielstattstr. 48, 81379 Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Laeis</LastName>
            <ForeName>Petra</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Daiichi Sankyo Europe GmbH, Zielstattstr. 48, 81379 Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manu</LastName>
            <ForeName>Marius Constantin</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Daiichi Sankyo Europe GmbH, Zielstattstr. 48, 81379 Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reimitz</LastName>
            <ForeName>Paul-Egbert</ForeName>
            <Initials>PE</Initials>
            <AffiliationInfo>
              <Affiliation>Daiichi Sankyo Europe GmbH, Zielstattstr. 48, 81379 Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Caterina</LastName>
            <ForeName>Raffaele</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Chair of Cardiology, University of Pisa, Lungarno Antonio Pacinotti, 43, 56126 Pisa, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kirchhof</LastName>
            <ForeName>Paulus</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cardiovascular Sciences, University of Birmingham, SWBH and UHB NHS Trusts, IBR 136, Wolfson Drive, Birmingham B15 2TT, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, University Heart and Vascular Centre Hamburg, Villa Garbrecht, Martinistraße 52, 20251 Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Atrial Fibrillation NETwork (AFNET), Münster, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Eur Heart J Cardiovasc Pharmacother</MedlineTA>
        <NlmUniqueID>101669491</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D065427">Factor Xa Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>NDU3J18APO</RegistryNumber>
          <NameOfSubstance UI="C552171">edoxaban</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065427" MajorTopicYN="N">Factor Xa Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Atrial fibrillation</Keyword>
        <Keyword MajorTopicYN="Y">Edoxaban</Keyword>
        <Keyword MajorTopicYN="Y">Non-vitamin K oral anticoagulant</Keyword>
        <Keyword MajorTopicYN="Y">Real-world</Keyword>
        <Keyword MajorTopicYN="Y">Registry</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32790837</ArticleId>
        <ArticleId IdType="pmc">PMC8117428</ArticleId>
        <ArticleId IdType="doi">10.1093/ehjcvp/pvaa079</ArticleId>
        <ArticleId IdType="pii">5892258</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H-C, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P; ESC Scientific Document Group. 
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–2962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27567408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385–1413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22923145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM.. 
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24315724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY.. 
The changing landscape for stroke prevention in AF: findings from the GLORIA-AF Registry Phase 2. J Am Coll Cardiol 2017;69:777–785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28209218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim H, Lee YS, Kim TH, Cha MJ, Lee JM, Park J, Park JK, Kang KW, Shim J, Uhm JS, Park HW, Choi EK, Kim JB, Kim C, Kim J, Joung B.. 
A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF). Korean J Intern Med 2020;35:99–108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6960047</ArticleId>
            <ArticleId IdType="pubmed">31014064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Monelli M, Molteni M, Cassetti G, Bagnara L, De Grazia V, Zingale L, Zilli F, Bussotti M, Totaro P, De Maria B, Dalla Vecchia LA.. 
Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study—data from the REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA). Vasc Health Risk Manag 2019;15:19–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6378887</ArticleId>
            <ArticleId IdType="pubmed">30833810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li G, Lip GYH, Holbrook A, Chang Y, Larsen TB, Sun X, Tang J, Mbuagbaw L, Witt DM, Crowther M, Thabane L, Levine M.. 
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol 2019;34:173–190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29948370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Lingohr-Smith M, Menges B, Lin J.. 
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin 2017;33:1745–1754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28849676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency. Lixiana: Summary of product characteristics 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana#product-information-section (6 July 2020).</Citation>
        </Reference>
        <Reference>
          <Citation>
Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F, Murphy SA, Kimura T, Jin J, Lanz H, Mercuri M, Braunwald E, Antman EM.. 
Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc 2016;5:e003432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4889207</ArticleId>
            <ArticleId IdType="pubmed">27207971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E.. 
Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 2016;134:24–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27358434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, Aylward P, White H, Zamorano JL, Antman EM, Ruff CT.. 
Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J Am Coll Cardiol 2016;68:1169–1178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27609678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, Lopez-de-Sa E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Reimitz PE, Kirchhof P.. 
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. J Cardiovasc Med (Hagerstown) 2019;20:97–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30540648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, Lopez-de-Sa E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Kerschnitzki M, Reimitz PE, Kirchhof P; on behalf of the ETNA-AF-Europe investigators. 
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). BMC Cardiovasc Disord 2019;19:165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6625115</ArticleId>
            <ArticleId IdType="pubmed">31299906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chao TF, Chen SA, Ruff CT, Hamershock RA, Mercuri MF, Antman EM, Braunwald E, Giugliano RP.. 
Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J 2019;40:1518–1527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30590425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG; XANTUS Investigators. 
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37:1145–1153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4823634</ArticleId>
            <ArticleId IdType="pubmed">26330425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lip GYH; EORP-AF Long-Term General Registry Investigators. 
Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace 2019;21:1013–1022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30904925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S.. 
Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke 2018;49:2933–2944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6257512</ArticleId>
            <ArticleId IdType="pubmed">30571400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Denas G, Gennaro N, Ferroni E, Fedeli U, Saugo M, Zoppellaro G, Padayattil Jose S, Costa G, Corti MC, Andretta M, Pengo V.. 
Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naive patients with non-valvular atrial fibrillation: propensity score matched cohort study. Int J Cardiol 2017;249:198–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28935464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ.. 
Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. Eur Heart J Cardiovasc Pharmacother 2019;5:70–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30423165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP; ORBIT-AF Investigators and Patients. 
Off-label dosing of non-vitamin k antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. J Am Coll Cardiol 2016;68:2597–2604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27978942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sabbag A, Yao X, Siontis KC, Noseworthy PA.. 
Anticoagulation for stroke prevention in older adults with atrial fibrillation and comorbidity: current evidence and treatment challenges. Korean Circ J 2018;48:873–889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6158453</ArticleId>
            <ArticleId IdType="pubmed">30238705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Madhavan M, Holmes DN, Piccini JP, Ansell JE, Fonarow GC, Hylek EM, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Chan P, Allen LA, Gersh BJ.. 
Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. Am Heart J 2019;211:77–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30901602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hanon O, Vidal JS, Le Heuzey JY, Kirchhof P, De Caterina R, Schmitt J, Laeis P, Mannucci PM, Marcucci M.. 
Oral anticoagulant use in octogenarian European patients with atrial fibrillation: a subanalysis of PREFER in AF. Int J Cardiol 2017;232:98–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28111055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pugh D, Pugh J, Mead GE.. 
Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011;40:675–683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21821732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim HM, Choi EK, Park CS, Cha MJ, Lee SY, Kwon JM, Oh S.. 
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation. PLoS One 2019;14:e0211766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6405244</ArticleId>
            <ArticleId IdType="pubmed">30845196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hohmann C, Hohnloser SH, Jacob J, Walker J, Baldus S, Pfister R.. 
Non-vitamin K oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients with non-valvular atrial fibrillation. Thromb Haemost 2019;119:971–980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30900223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM.. 
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015;385:2288–2295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25769361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Garcia DA, Lopes RD, Hylek EM.. 
New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010;104:1099–1105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20886196</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
